Active, not recruiting |
: Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
: - Endometrial Adenocarcinoma
- Endometrial Endometrioid Adenocarcinoma
-
- Acinar Cell Carcinoma
- Adrenal Cortex Carcinoma
- Adrenal Gla
: 2016-07-13
: - Procedure: Biospecimen Collection
|
Recruiting |
: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
: - Ovarian Brenner Tumor
- Ovarian Carcinosarcoma
- Ovarian Clear
: 2014-03-28
: - Drug: Gemcitabine Hydrochloride
|
Recruiting |
: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers
: - Cervical Adenosarcoma
- Cervical Adenosquamous Carcinoma
- Cer
: 2013-12-19
: - Biological: Bevacizumab Given
|
Recruiting |
: Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
: - Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
-
- Drug: Cabozantinib S-malate Gi
|
Active, not recruiting |
: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
: - Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
-
- Drug: Carboplatin Given IV
|
Active, not recruiting |
: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
: - Cognitive Side Effects of Cancer Therapy
- Malignant Ovarian Epithelial Tumor
-
- Procedure: Cognitive Assessment
|
Active, not recruiting |
: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
: - Adult Hepatocellular Carcinoma
- Advanced Adult Hepatocellular Carcinoma
-
- Biological: Bevacizumab Given
|
Active, not recruiting |
: Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
: - Fallopian Tube Carcinosarcoma
- Fallopian Tube Clear Cell Adenocarcinoma
-
- Biological: Bevacizumab Given
|
Active, not recruiting |
: Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
: - Ovarian Carcinosarcoma
- Recurrent Fallopian Tube Carcinoma
: 2009-08-06
: - Drug: Paclitaxel Given IV
|